New era of immunotherapy for colorectal cancer
10.3760/cma.j.issn.1008?6315.2017.09.023
- VernacularTitle:结直肠癌免疫治疗新时代
- Author:
Ziwen ZHANG
;
Tingting ZHANG
;
Yuxian BAI
- Keywords:
Colorectal cancer;
Immunotherapy;
Immune checkpoint inhibitors;
Cytokine therapy;
Toll?like receptors agonists;
Adoptive cell therapy
- From:
Clinical Medicine of China
2017;33(9):861-864
- CountryChina
- Language:Chinese
-
Abstract:
Colorectal cancer is one of the common malignant tumors and the overall prognosis is poor. The search for a more effective treatment for colorectal cancer has never stopped. The current interaction between the modulated immune system and the tumor microenvironment is a hot topic in the treatment of colorectal cancer. The achievements involve immune checkpoint inhibition, cytokine therapy, toll?like receptors and autologous cell therapy. It has been proved that these methods have mild effect on tumor loading reduction. However, significant breakthrough has been achieved with the use of checkpoint inhibitors targeting cytotoxic T lymphocyte associated antigen?4 (CTLA?4),programmed death?1 (PD?1) and programmed death receptor ligand 1 (PD?L1). Immunotherapy is promising in the treatment of patients with refractory tumors. The success of this current immunotherapy approach is largely limited to tumors with high mutation amplification, such as melanoma,renal cell carcinoma ( RCC) and non?small cell lung cancer. However,this discovery has led the development of checkpoint inhibitors in the treatment of colorectal cancer with highly mutated amplification of mismatch repair gene to a new era.
